Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: Desidustat as a add on therapy with erythropoietin alpha as a treatment group: The treatment protocol of desidustat was 50 mg BD for morning and night for weekly thrice an alternate day
Sponsors
Arivazhagan S
Eligibility
Inclusion criteria
Inclusion criteria: ESRD patients on maintenance hemodialysis with anemia (hemoglobin level below 8g/dl) and receiving erythropoietin alpha and iron injection.
Exclusion criteria
Exclusion criteria: Patient with red blood cell transfusion (within 4 weeks) History of renal transplantation Previous or concurrent cancer Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in the hemoglobin level in hyporesponsive state The adjunct therapy will be better when compared with control treatment Can able to assess the safety of the treatmentTimepoint: Hemoglobin Hematocrit The hemoglobin and hematocrit value follow up to the baseline, after 4th week, 8th week and 12th week | — |
Secondary
| Measure | Time frame |
|---|---|
| To reduce the number of hospital staysTimepoint: Number of hospital stay The hospital stay outcome calculated based on admission & discharge of patient (inpatient hospital days). in that days between the admission & discharge are used to identify the hospital stays | — |
Countries
India
Contacts
Public ContactArivazhagan S
PSG college of pharmacy
Outcome results
None listed